Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

Keyphrases

• Disease Diagnosis 100%
• Clinical Practice 100%
• Acute Myeloid Leukemia 100%
• Minimal Residual Disease 100%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 100%
• Disease Assessment 36%
• Next-generation Sequencing 18%
• Droplet Digital PCR (ddPCR) 18%
• Quantitative PCR 9%
• Leukemia 9%
• Pathological Examination 9%
• Polymerase Chain Reaction 9%
• Patient Management 9%
• Reaction-based 9%
• Next-generation Sequencing Technology 9%
• Peri 9%
• Specific Biomarkers 9%
• Multiparameter Flow Cytometry 9%
• Clinical Tool 9%
• Quality Assessment 9%
• Assessment Process 9%
• Retrospective Cohort Analysis 9%
• Error Analysis 9%
• Practical Assessment 9%

Medicine and Dentistry

• Acute Myeloid Leukemia 100%
• Minimal Residual Disease 100%
• Hematopoietic Cell 100%
• Cell Transplantation 100%
• Disease Assessment 36%
• Next Generation Sequencing 27%
• Droplet Digital Polymerase Chain Reaction 18%
• Clinician 9%
• Flow Cytometry 9%
• Biological Marker 9%
• Leukemia 9%
• Cohort Analysis 9%
• Transplantation 9%
• Polymerase Chain Reaction 9%
• Real-Time Polymerase Chain Reaction 9%

Immunology and Microbiology

• Hematopoietic Cell 100%
• Cell Transplantation 100%
• Next Generation Sequencing 100%
• Droplet Digital Polymerase Chain Reaction 66%
• Polymerase Chain Reaction 33%
• Real-Time Polymerase Chain Reaction 33%